87
Participants
Start Date
February 28, 2010
Primary Completion Date
April 30, 2012
Study Completion Date
May 31, 2012
ALN-RSV01
Administered by nebulization once daily for 5 days
Normal Saline
Administered by nebulization once daily for 5 days
Clinical Site, Vienna
Clinical Site, Darlinghurst
Clinical Site, Melbourne
Clinical Site, Adelaide
Clinical Site, Perth
Clinical Site, New York
Clinical Site, Berlin
Clinical Site, Pittsburgh
Clinical Site, Philadelphia
Clinical Site, Hamburg
Clinical Site, Atlanta
Clinical Site, Hanover
Clinical Site, Tampa
Clinical Site, Nashville
Clinical Site, Cleveland
Clinical Site, Essen
Clinical Site, Ann Arbor
Clinical Site, Chicago
Clinical Site, Chicago
Clinical Site, St Louis
Clinical Site, Homburg/Saar
Clinical Site, Strasbourg
Clinical Site, Dallas
Clinical Site, Paris
Clinical Site, Houston
Clinical Site, Denver
Clinical Site, Phoenix
Clinical Site, Los Angeles
Clinical Site, Boston
Clinical Site, Boston
Clinical Site, Edmonton
Clinical Site, Toronto
Clinical Site, Leipzig
Lead Sponsor
Alnylam Pharmaceuticals
INDUSTRY